MicroRNAs regulating apoptosis and delivery strategies for treating intervertebral disc degeneration

Yuwei Chen, Chuan Fei Guo, Weiqiang Lan, Yuheng Liu, Fei Ma, Daqiang Zheng, Xueyuan Xu, Qingquan Kong, Yu WangFrontiers in Cell and Developmental Biology 2025 · DOI

TL;DR

Intervertebral disc degeneration (IDD), a major cause of chronic low back pain, is driven by the death of nucleus pulposus cells (NPCs). This review explores how microRNAs (miRNAs) can be used to combat NPC apoptosis and discusses advanced delivery strategies, including targeting specific cells or organelles and using responsive materials, to effectively deliver these therapeutic miRNAs to the avascular intervertebral disc.

What Problem Does This Paper Address?

Chronic low back pain (LBP) is a global health crisis, with intervertebral disc degeneration (IDD) being a primary culprit. Current treatments for IDD primarily manage symptoms rather than addressing the root cause: the progressive death (apoptosis) of nucleus pulposus cells (NPCs) within the intervertebral disc (IVD). This cell death leads to the breakdown of the disc's structural components, causing pain and disability. While gene therapy using microRNAs (miRNAs) shows promise for reversing IDD by modulating apoptotic pathways, the unique avascular nature and harsh microenvironment of the IVD present significant challenges for effective delivery of these therapeutic agents. This paper aims to bridge this gap by reviewing the role of miRNAs in NPC apoptosis and detailing innovative delivery strategies designed to overcome these delivery hurdles.

Methods

This paper is a comprehensive review, synthesizing existing research rather than presenting new experimental data. The authors analyze and categorize various approaches based on:

  • miRNA Regulation of NPC Apoptosis: Reviewing the known molecular pathways (mitochondrial, ER, and death receptor pathways) involved in NPC apoptosis and identifying specific miRNAs that either promote or inhibit these processes.
  • Delivery Strategies:
    • Targeting Strategies:
      • NPC-targeting: Methods that ensure delivery specifically to NPCs, including direct cellular uptake, ligand-receptor interactions, and aptamer-based targeting.
  • Organelle-targeting: Strategies that deliver miRNAs directly to specific organelles within NPCs, such as mitochondria and the endoplasmic reticulum (ER), which are key players in apoptosis.
  • Responsive Delivery Strategies: Systems designed to release therapeutic miRNAs in response to specific stimuli:
  • Endogenous Stimuli: pH changes, reactive oxygen species (ROS), and enzyme activity, all of which are altered in the degenerated IVD microenvironment.
  • Exogenous Stimuli: External triggers like temperature, ultrasound, magnetism, and light, allowing for controlled and localized release.

Datasets

Not discussed in the paper. This is a review article summarizing existing literature.

Key Insights and Ideas

  • NPC Apoptosis is Central to IDD: The paper strongly emphasizes that the death of NPCs is not just a symptom but a critical driver of IDD, making it a prime therapeutic target.
  • miRNAs as Powerful Regulators: miRNAs are highlighted as potent regulators of gene expression, offering a precise way to modulate the complex apoptotic pathways within NPCs.
  • The IVD's "Delivery Problem": The avascular nature and dense extracellular matrix of the IVD create a significant barrier for conventional drug delivery, necessitating specialized strategies.
  • Multi-pronged Delivery Approach: The most promising therapeutic strategies involve a combination of targeting (to reach the right cells/organelles) and responsiveness (to release the miRNA at the right time and place).
  • Organelle-Targeting Offers Precision: Delivering miRNAs directly to mitochondria or the ER, key sites of apoptosis, offers a more targeted and potentially more effective approach than general cellular delivery.
  • Mimicking the Degenerated Environment: Responsive delivery systems that utilize the altered pH, ROS levels, or enzyme activity within a degenerated disc can achieve highly localized and controlled drug release.

Key Results

As a review, this paper doesn't present new quantitative results. Instead, it synthesizes findings from numerous studies, highlighting:

  • Identification of Key miRNAs: Numerous miRNAs have been identified that either promote or inhibit NPC apoptosis, with specific examples provided for their roles in different apoptotic pathways (e.g., miR-143, miR-222 for mitochondrial pathway; miR-155, miR-499a-5p for DR pathway).
  • Advancements in Nanocarriers: The review details various nanocarrier systems (e.g., nanoparticles, exosomes, hydrogels) that have been engineered for miRNA delivery, demonstrating improved cellular uptake, stability, and controlled release.
  • Successful Targeting and Responsive Systems (Pre-clinical): Numerous examples are cited where targeting strategies (e.g., aptamers, ligand-receptor binding) and responsive systems (e.g., pH-sensitive hydrogels, ROS-responsive materials) have shown promise in preclinical models for delivering therapeutic agents to the IVD.

Limitations and Future Work

  • Delivery Efficiency and Stability: A major challenge remains the low transfection efficiency of miRNAs and their susceptibility to degradation, necessitating robust delivery systems.
  • Off-Target Effects and Immunogenicity: Ensuring that delivered miRNAs only act on target cells and do not elicit unwanted immune responses is crucial.
  • In Vivo Validation: While many strategies show promise in vitro, extensive in vivo studies, particularly in larger animal models and eventually human trials, are needed to confirm safety and efficacy.
  • Complexity of IVD Microenvironment: The interplay of various factors in IDD requires sophisticated delivery systems that can respond to multiple stimuli.
  • Clinical Translation Gap: The paper notes that most delivery systems are still in the bench-to-bedside phase, with limited clinical trials for miRNA-based IDD therapies.
  • Future Directions: The authors suggest developing multimodal delivery systems that combine targeting and responsiveness, exploring combination therapies (miRNA with other drugs), and conducting more rigorous preclinical and clinical evaluations.

Summary updated

Abstract

Intervertebral disc degeneration (IDD) is a leading contributor to chronic low back pain (LBP), significantly impairing quality of life and imposing socioeconomic burdens globally. Current treatments fail to address the underlying pathology or restore intervertebral disc (IVD) function. IDD is multifactorial but strongly linked to nucleus pulposus cell (NPC) apoptosis. Gene therapy, particularly the use of microRNAs (miRNAs), holds promise for reversing IDD by targeting apoptotic pathways and enhancing the biological functions of NPCs. Given the avascular nature of IVD, effective delivery strategies are critical. Targeting strategies, such as NPC-targeting, which relies on cellular uptake through direct uptake, specific ligand‒receptor interactions and aptamer utilization, can significantly increase delivery efficacy. Additionally, organelle-targeting strategies that focus on mitochondria and the endoplasmic reticulum (ER) optimize therapeutic delivery. Coupled with these targeting methods, responsive delivery strategies that react to endogenous stimuli (such as pH, reactive oxygen species, and enzymes) and exogenous stimuli (including temperature, ultrasound, magnetism, and light) enable spatiotemporal release of therapeutic agents. This review summarizes the role of anti-apoptotic miRNAs in regulating NPC apoptosis and the latest advances in targeting and responsive delivery strategies to overcome the challenges associated with targeted therapeutic miRNA application, offering new insights into the treatment of IDD.
BibTeX
@inproceedings{chen2025micrornas,
  author = {Yuwei Chen and Chuan Fei Guo and Weiqiang Lan and Yuheng Liu and Fei Ma and Daqiang Zheng and Xueyuan Xu and Qingquan Kong and Yu Wang},
  title = {{MicroRNAs regulating apoptosis and delivery strategies for treating intervertebral disc degeneration}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  doi = {10.3389/fcell.2025.1683247},
}
Figure